about
Liver flukes: the malady neglectedDiagnostic and therapeutic biomarkers in pancreaticobiliary malignancyCancer review: CholangiocarcinomaThe significance of genetics for cholangiocarcinoma developmentBiliary strictures: diagnostic considerations and approach.CholangiocarcinomaMucins in neoplasms of pancreas, ampulla of Vater and biliary systemClassification, diagnosis, and management of cholangiocarcinomaDiagnosis of cholangiocarcinoma.Detection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a new diagnostic tool in patients with biliary strictures.Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma.Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitorsUpdate on the management of cholangiocarcinoma.Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates.Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatographyIdentification of a Novel Biomarker for Biliary Tract Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass SpectrometryNew insights on cholangiocarcinoma.Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma.Diagnostic approaches for cholangiocarcinoma.Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease.Cancer surveillance in patients with primary sclerosing cholangitis.Molecular diagnosis of intrahepatic cholangiocarcinoma.Perioperative Management of Hilar Cholangiocarcinoma.Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis.Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancerSarcopenia as a prognostic factor in hepatolithiasis-associated intrahepatic cholangiocarcinoma patients following hepatectomy: a retrospective study.MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer.Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.Malignancies in Primary Sclerosing Cholangitis--A Continuing ThreatThe diagnostic performance of serum MUC5AC for cholangiocarcinoma: A systematic review and meta-analysisClinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoproteinUltrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology.Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.Cholangiocarcinoma: has there been any progress?Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers.Preoperative serum CA 19-9 level as a predictive factor for recurrence after curative resection in biliary tract cancer.Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT).Novel diagnostic and prognostic biomarkers in biliary tract cancer.Bile proteome in health and disease.
P2860
Q24598799-4A0481EA-790B-43AE-B532-D9E3BF2D8DF7Q26767120-6CE59B20-43EA-4F6D-92FE-FE3182A78B8FQ26865200-D092EC4D-7D4D-4AA9-9127-9CF754FF357CQ26865749-3DBDD6F0-B385-4BEA-B4B3-ED8F7FB631FDQ26998582-F0D0521B-269F-4F25-A4A2-4E53F70CC7B5Q27001694-433B19BB-411E-4AD1-8636-2B9EBAFA32E9Q28070355-BD872577-9F6F-4477-9396-E98BD5B7DDEEQ28275153-96DF06CE-F355-41AA-A228-63D699134704Q30493559-963F31BF-A678-410F-B40F-39338139C04EQ31081531-26209ACC-91F9-4F30-939E-2463A70F7056Q33437197-1F7A2EF3-7675-460F-BC88-13C403DA1276Q33605089-563214FE-9496-4217-87E5-D74D92E3EC90Q34104493-737E1BA5-46CF-44C3-8CD0-029BFD99D527Q34153255-20D56B61-EAF1-4731-A40D-78C2E6A5C889Q34186338-8CCDBDE8-6CB9-4E0B-A1EB-A56CB4C85705Q34239695-0203B660-0ABB-46E8-A97A-3B44D60B6636Q34377996-FC493167-BAB0-4329-8962-FE23C3446D86Q34391135-D4ED2B63-2DA5-4D72-8D84-4A50B795FF2BQ34464452-BBF794E9-5CDD-4F53-9C43-9E6E32F93DFAQ34594430-A899A8DC-07FA-4703-9213-80558B558AF5Q35206399-4B247242-C88C-41AD-8E11-D69596E0248EQ35490961-2A9A4C89-B03A-412D-93AE-20BE2C70A7F8Q35592221-6CFC47B3-103B-4D22-80FF-5FFAF23826FBQ35645739-F60AF0B8-810B-4ABF-9937-CEE7F8A66DF4Q36306293-2A066F7A-0208-4222-907A-AB3A0A7876DAQ36381459-8B864FEA-DEA9-4EE7-84F4-03A605FB5747Q36411789-D87776D4-A6E4-4BFC-B38A-DEE296823ABAQ36667483-66BE7489-64EB-4F3B-A793-D9FBC9742585Q36900063-F2E8E16C-B6EB-4996-B416-BB7D5BA6DB29Q37082378-FBBC67E1-C148-4BEC-8CEA-9980644F8B8CQ37205543-6786B820-DE6E-494C-8400-D63F7BFC7F6EQ37245513-7EA245DC-0162-4DEB-9F10-B76BA4C524D7Q37396267-3F877C13-0969-48DF-AC2E-CC833288A0B5Q37697170-486BEABF-2886-46CA-A301-A5A3C7637065Q37698980-F803696B-870D-409F-B9A2-7C5CA382AD47Q37734427-D3E18C05-1071-44D7-ABAF-74F76C60EFEFQ37826379-C11A691B-83F6-4D87-893A-F94A4A613CBBQ37861563-3709E954-6F36-4139-B18A-B897F8496A73Q38131056-532B220D-A39B-4EEF-8D0C-53C26BDEFB0FQ38201380-35DC445C-91C0-4B03-9C1E-2B4175E770A8
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Serum and bile markers for cholangiocarcinoma.
@ast
Serum and bile markers for cholangiocarcinoma.
@en
type
label
Serum and bile markers for cholangiocarcinoma.
@ast
Serum and bile markers for cholangiocarcinoma.
@en
prefLabel
Serum and bile markers for cholangiocarcinoma.
@ast
Serum and bile markers for cholangiocarcinoma.
@en
P2093
P356
P1476
Serum and bile markers for cholangiocarcinoma.
@en
P2093
Bodo Klump
Michael Gregor
Oliver Nehls
P304
P356
10.1055/S-2004-828891
P577
2004-05-01T00:00:00Z